发明名称 Vitronectin receptor antagonist pharmaceuticals
摘要 The present invention describes novel compounds of the formula: <?in-line-formulae description="In-line Formulae" end="lead"?>(Q)<SUB>d</SUB>-L<SUB>n</SUB>-C<SUB>h</SUB>,<?in-line-formulae description="In-line Formulae" end="tail"?> useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
申请公布号 US7321045(B2) 申请公布日期 2008.01.22
申请号 US20040770380 申请日期 2004.02.02
申请人 BRISTOL-MYERS SQUIBB PHARMA COMPANY 发明人 RAJOPADHYE MILIND;HARRIS THOMAS D.;CHEESMAN EDWARD H.
分类号 C07D231/54;A61K31/33;A61K31/416;A61K49/00;A61K51/00;C07D259/00;C07D401/12;C07D401/14;C07K5/02;C07K5/06;C07K5/078 主分类号 C07D231/54
代理机构 代理人
主权项
地址